TNF-α -308 G>A polymorphism and risk of bone marrow failure syndrome: A meta-analysis

Gene

Volumn 565, Issue 1, 2015, Pages 1-8

  Chen, Wancheng ^a,b   Zhu, Haili ^a   Yu, Lili ^a   Lu, Ziyuan ^a   Yao, Zhuoxin ^a,b   Xiao, Yang ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Bone marrow failure syndrome; Meta analysis; Polymorphism; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TNF PROTEIN, HUMAN;

ALLELE; APLASTIC ANEMIA; ASIAN; BONE MARROW DEPRESSION; CASE CONTROL STUDY; CAUCASIAN; CHINESE BIOMEDICAL DATABASE; CNKI DATABASE; DNA POLYMORPHISM; DOMINANT GENE; ETHNICITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MEDLINE; META ANALYSIS; MYELODYSPLASTIC SYNDROME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RECESSIVE GENE; REVIEW; SAMPLE SIZE; SENSITIVITY ANALYSIS; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANEMIA, APLASTIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928415193     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.04.038     Document Type: Review

References (42)

1. Awad M.R., El-Gamel A., Hasleton P., Turner D.M., Sinnott P.J., Hutchinson I.V. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 66:1014-1020.
2. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
3. Bejar R., Steensma D.P. Recent developments in myelodysplastic syndromes 2014, 124:2793-2803.
4. Belli C.B., Bestach Y., Sieza Y., Gelemur M., Giunta M., Flores M.G., Watman N., Bengio R., Larripa I. The presence of -308A TNFalpha is associated with anemia and thrombocytopenia in patients with myelodysplastic syndromes. Blood Cells Mol. Dis. 2011, 47:255-258.
5. Bestach Y., Sieza Y., Attie M., Riccheri C., Verri V., Bolesina M., Bengio R., Larripa I., Belli C. Polymorphisms in TNF and IFNG are associated with clinical characteristics of aplastic anemia in Argentinean population. Leuk. Lymphoma 2015, 1-6.
6. Bouma G., Crusius J.B., Oudkerk Pool M., Kolkman J.J., von Blomberg B.M., Kostense P.J., Giphart M.J., Schreuder G.M., Meuwissen S.G., Pena A.S. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand. J. Immunol. 1996, 43:456-463.
7. Brodsky R.A. Paroxysmal nocturnal hemoglobinuria. Blood 2014, 124:2804-2811.
8. Demeter J., Messer G., Schrezenmeier H. Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann. Hematol. 2002, 81:566-569.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
10. Egger M., Smith G.D. Bias in location and selection of studies. BMJ 1998, 316:61-66.
11. El Mahgoub I.R., Afify R.A., Botros S.K., Fawzy R. Immunoregulatory cytokines gene polymorphisms in Egyptian patients affected with acquired aplastic anemia. Ann. Hematol. 2014, 93:923-929.
12. Fermo E., Bianchi P., Barcellini W., Pedotti P., Boschetti C., Alfinito F., Cortelezzi A., Zanella A. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur. J. Immunogenet. 2004, 31:267-269.
13. Galili N., Raza A. Immunomodulatory drugs in myelodysplastic syndromes. Expert Opin. Investig. Drugs 2006, 15:805-813.
14. Geissler K. Pathophysiology and treatment of aplastic anemia. Wien. Klin. Wochenschr. 2003, 115:444-450.
15. Gidvani V., Ramkissoon S., Sloand E.M., Young N.S. Cytokine gene polymorphisms in acquired bone marrow failure. Am. J. Hematol. 2007, 82:721-724.
16. Gowans D., O'Sullivan A., Rollinson S., Roddam P., Groves M., Fegan C., Morgan G., Bowen D. Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology. Br. J. Haematol. 2002, 117:541-545.
17. Gyulai Z., Balog A., Borbenyi Z., Mandi Y. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol. Immunol. Hung. 2005, 52:463-475.
18. Hajeer A.H., Hutchinson I.V. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum. Immunol. 2001, 62:1191-1199.
19. Jhanwar S.C. Genetic and epigenetic pathways in myelodysplastic syndromes: a brief overview. Adv. Biol. Regul. 2014, 10.1016/j.jbior.2014.11.002.
20. Kadar K., Demeter J., Andrikovics H., Tordai A., Kovacs M., Fust G., Karadi I., Varkonyi J. TNF-alpha promoter gene polymorphism in patients with myelodysplastic syndrome. Acta Haematol. 2005, 113:262-264.
21. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997, 34:391-399.
22. Lee Y.G., Kim I., Kim J.H., Bae J.Y., Kwon J.H., Shin D.Y., Lee J.E., Song E.Y., Kim H.K., Yoon S.S., Park S.S., Lee D.S., Han K.S., Park M.H., Hong Y.C., Park S., Kim B.K. Impact of cytokine gene polymorphisms on risk and treatment outcomes of aplastic anemia. Ann. Hematol. 2011, 90:515-521.
23. Li J., Yang S., Lu S., Zhao H., Feng J., Li W., Ma F., Ren Q., Liu B., Zhang L., Zheng Y., Han Z.C. Differential gene expression profile associated with the abnormality of bone marrow mesenchymal stem cells in aplastic anemia. PLoS One 2012, 7:e47764.
24. Li K., Yang M., Sablok G., Fan J., Zhou F. Screening features to improve the class prediction of acute myeloid leukemia and myelodysplastic syndrome. Gene 2013, 512:348-354.
25. Lunn R.A., Sumar N., Bansal A.S., Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology 2005, 10:107-114.
26. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
27. Newell L.F., Gooley T., Hansen J.A., Stirewalt D.L., Petersdorf E.W., Deeg H.J. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol. Blood Marrow Transplant. 2010, 16:1700-1706.
28. Parnes A., Nikiforow S., Berliner N., Vanasse G.J. Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome. Br. J. Haematol. 2010, 150:700-701.
29. Passweg J.R. Anemia with aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes. Ther. Umsch. 2010, 67:251-255.
30. Pavy S., Toonen E.J., Miceli-Richard C., Barrera P., van Riel P.L., Criswell L.A., Mariette X., Coenen M.J. Tumour necrosis factor alpha -308G→A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann. Rheum. Dis. 2010, 69:1022-1028.
31. Peng J., Liu C., Zhu K., Zhu Y., Yu Y., Li J., Hou M., Chen X., Xu C., Zhang M. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum. Immunol. 2003, 64:896-901.
32. Powers M.P., Nishino H., Luo Y., Raza A., Vanguri A., Rice L., Zu Y., Chang C.C. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch. Pathol. Lab. Med. 2007, 131:1789-1793.
33. Schrezenmeier H., Korper S., Hochsmann B. Aplastic anemia. Dtsch. Med. Wochenschr. 2014, 139:2503-2506.
34. Secchiero P., Zauli G. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr. Opin. Hematol. 2008, 15:42-48.
35. Shen W., Clemente M.J., Hosono N., Yoshida K., Przychodzen B., Yoshizato T., Shiraishi Y., Miyano S., Ogawa S., Maciejewski J.P., Makishima H. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 2014, 124:4529-4538.
36. Sri Manjari K., Jyothy A., Shravan Kumar P., Prabhakar B., Uma Devi M., Ramanna M., Nallari P., Venkateshwari A. A single-nucleotide polymorphism in tumor necrosis factor-alpha (-308 G/A) as a biomarker in chronic pancreatitis. Gene 2014, 539:186-189.
37. Townsley D.M., Young N.S. Blood consult: paroxysmal nocturnal hemoglobinuria and its complications. Blood 2013, 122:2795-2798.
38. Visconte V., Tiu R.V., Rogers H.J. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014, 49:216-227.
39. Visconte V., Lindsley R.C., Berlyne D. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014. Leuk. Res. 2015, 39:110-113.
40. Wang S.Y., Yang X.J., Yang S.S., Wang W., Tian Y.Y., Cao F.L., Zhou J. Association analysis of cytokine polymorphisms and plasma level in Northern Chinese Han patients with paroxysmal nocturnal hemoglobinuria. Chin. Med. J. (Engl.) 2012, 125:1576-1580.
41. Willis L., Rexwinkle A., Bryan J., Kadia T.M. Recent developments in drug therapy for aplastic anemia. Ann. Pharmacother. 2014, 48:1469-1478.
42. Xu J.Q., Wang J.Y., Qin T.J., Xu Z.F., Fang L.W., Pan L.J., Hu N.B., Zhang H.L., Qu S.Q., Zhang Y., Xiao Z.J. Relationship between polymorphisms of tumor necrosis factor alpha gene and primary myelodysplastic syndromes. Zhonghua Xue Ye Xue Za Zhi 2013, 34:873-876.